MX9301922A - Composiciones para el tratamiento de infeccion y enfermedad ocasionadas por el virus de hepatitis b (hbv). - Google Patents

Composiciones para el tratamiento de infeccion y enfermedad ocasionadas por el virus de hepatitis b (hbv).

Info

Publication number
MX9301922A
MX9301922A MX9301922A MX9301922A MX9301922A MX 9301922 A MX9301922 A MX 9301922A MX 9301922 A MX9301922 A MX 9301922A MX 9301922 A MX9301922 A MX 9301922A MX 9301922 A MX9301922 A MX 9301922A
Authority
MX
Mexico
Prior art keywords
hbv
hepatitis
virus
infection
treatment
Prior art date
Application number
MX9301922A
Other languages
English (en)
Inventor
Dennis W Adair
Kenneth A Smile
Dannie King
Original Assignee
Oclassen Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oclassen Pharma Inc filed Critical Oclassen Pharma Inc
Publication of MX9301922A publication Critical patent/MX9301922A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con composiciones farmacéuticas útiles para el tratamiento de pacientes que adolecen de una infección o enfermedad ocasionada por el virus de hepatitis B (HBV). En particular, se ha descubierto que la administración de cantidades de dosificación baja de 1-(2'-deoxi-2'-fluoro-beta-D-arabinofuranosil)-5- yodouracilo (FIAU) a seres humanos infectados crónicamente con HBV, es efectiva para reducir drásticamente los marcadores de circulación asociados con HBV, la presente invención está también dirigida a métodos para la preparación de las composiciones antivirales farmacéuticas.
MX9301922A 1992-04-06 1993-04-02 Composiciones para el tratamiento de infeccion y enfermedad ocasionadas por el virus de hepatitis b (hbv). MX9301922A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86389092A 1992-04-06 1992-04-06
US95292792A 1992-09-25 1992-09-25
US07/959,004 US5432165A (en) 1992-04-06 1992-10-09 Methods for the treatment of infection caused by Hepatitis B virus (HBV)

Publications (1)

Publication Number Publication Date
MX9301922A true MX9301922A (es) 1993-10-01

Family

ID=27420427

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9301922A MX9301922A (es) 1992-04-06 1993-04-02 Composiciones para el tratamiento de infeccion y enfermedad ocasionadas por el virus de hepatitis b (hbv).

Country Status (26)

Country Link
US (1) US5432165A (es)
EP (1) EP0565412A1 (es)
JP (1) JPH069403A (es)
CN (1) CN1081879A (es)
AP (1) AP372A (es)
AU (1) AU662804B2 (es)
BE (1) BE1009181A5 (es)
BR (1) BR9306207A (es)
CA (1) CA2092356A1 (es)
EE (1) EE9400068A (es)
ES (1) ES2105923B1 (es)
FR (1) FR2689398B1 (es)
GR (1) GR930100111A (es)
IL (1) IL105169A0 (es)
IT (1) IT1264332B1 (es)
LV (1) LV10191B (es)
MD (1) MD940152A (es)
MX (1) MX9301922A (es)
NO (1) NO931246L (es)
NZ (1) NZ247188A (es)
OA (1) OA10102A (es)
PH (1) PH31116A (es)
PT (1) PT101238A (es)
SI (1) SI9300144A (es)
WO (1) WO1993019762A1 (es)
YU (1) YU23993A (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346627B1 (en) 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
WO1996010649A1 (en) * 1994-09-30 1996-04-11 Southwest Foundation For Biomedical Research Isolated human hepatitis b virus polymerase and uses thereof
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US6296882B1 (en) * 2000-06-12 2001-10-02 Manuel Viamonte, Jr. Non-toxic mucosal disinfectant containing isopropyl alcohol, sesame oil, and lemon oil
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
JP2012526149A (ja) * 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE147774C (es) *
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4594339A (en) * 1982-04-06 1986-06-10 Sloan-Kettering Institute For Cancer Research Anti-herpes virus compositions containing 5-substituted 1-2'(deoxy-2-'-substituted-β-d-arabinofuranosyl)pyrimedene nucleosides
US4666892A (en) * 1984-03-06 1987-05-19 Sloan-Kettering Memorial Cancer Center Method and composition for hepatitis treatment with pyrimidine nucleoside compounds

Also Published As

Publication number Publication date
PT101238A (pt) 1994-03-31
US5432165A (en) 1995-07-11
WO1993019762A1 (en) 1993-10-14
AU662804B2 (en) 1995-09-14
OA10102A (en) 1996-12-18
SI9300144A (en) 1994-03-31
JPH069403A (ja) 1994-01-18
CA2092356A1 (en) 1993-10-07
EE9400068A (et) 1995-12-15
AU3530293A (en) 1993-10-07
ES2105923B1 (es) 1998-07-01
EP0565412A1 (en) 1993-10-13
ITTO930226A1 (it) 1994-10-05
BE1009181A5 (fr) 1996-12-03
FR2689398A1 (fr) 1993-10-08
LV10191B (en) 1995-04-20
GR930100111A (el) 1993-12-30
FR2689398B1 (fr) 1994-11-18
NZ247188A (en) 1995-05-26
PH31116A (en) 1998-02-28
MD940152A (ro) 1995-12-31
IL105169A0 (en) 1993-07-08
YU23993A (sh) 1997-05-28
ES2105923A1 (es) 1997-10-16
IT1264332B1 (it) 1996-09-23
BR9306207A (pt) 1998-06-23
AP9300513A0 (en) 1993-04-30
NO931246L (no) 1993-10-07
AP372A (en) 1994-11-24
LV10191A (lv) 1994-10-20
CN1081879A (zh) 1994-02-16
ITTO930226A0 (it) 1993-04-05
NO931246D0 (no) 1993-03-31

Similar Documents

Publication Publication Date Title
BR0312286A (pt) pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae
ATE157257T1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
FI904445A0 (fi) Antivirala foereningar.
BR9810745A (pt) Derivados de benzimidazol
PT911033E (pt) Utilizacao do interferao de consenso para a reducao dos efeitos secundarios do tratamento com interferoes na hepatite viral
ES2069582T3 (es) Nucleosidos terapeuticos.
PT88930A (pt) Processo para a preparacao de novos analogos de nucleosidos e de composicoes farmaceuticas que os contem
RU95110698A (ru) Способ лечения инфекций, вызываемых вирусом гепатита в
WO1998004290A3 (en) Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders
MX9606732A (es) Compuestos terapeuticos.
EP0270317A3 (en) Pharmaceutical compositions for the treatment of diseases caused by viruses
MX9301922A (es) Composiciones para el tratamiento de infeccion y enfermedad ocasionadas por el virus de hepatitis b (hbv).
BR9913333A (pt) Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos
KR950701638A (ko) 푸린 동족체의 항비루스성 포스폰산 유도체(Antiviral phosphonic acid derivatives of purine analogues)
DK178188D0 (da) Antivirusmiddel
BG100599A (en) Antiviral form and therapeutical method
ATE79034T1 (de) Behandlung von viruskrankheiten.
KR910005886A (ko) 안정화 백혈구 인터페론
DK0469064T3 (da) Anvendelse af C-20- til C-26-alifatiske alkoholer til fremstilling af et lægemiddel til behandling af virusinfektioner
BR9916043A (pt) Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes
DE69019404D1 (de) Derivate von Penciclovir zur Behandlung von Hepatitis-B-Infektionen.
ES2148234T3 (es) Composicion farmaceutica a base de flavopereirina y su utilizacion en el tratamiento del virus vih.
KR900701278A (ko) 바이러스 감염 치료용 담즙산
ES2136061T3 (es) Nucleosidos terapeuticos.
MX9303985A (es) Nucleosidos terapeuticos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal